-transparent.png){kind=logo}
The centrally acting cholinergic antagonist scopolamine (0.025-0.10 mg/kg ip) and the peripherally acting cholinergic antagonist methyl-scopolamine (0.01-0.10 mg/kg) dose dependently impaired discriminability independent of delay in a delayed conditional discrimination task that precludes use of mediating behavior. This indicates that scopolamine does not specifically affect working memory. Drugs that enhance cholinergic transmission neither improved discriminability nor attenuated scopolamine-induced impairments. In a post hoc analysis scopolamine was found to impair discriminability in a delay-dependent manner in rats that performed at a high level in pretest sessions. Methyl-scopolamine impaired performance independently of delay in these rats. The authors suggest that a ceiling effect at short delays produced this Drug x Delay interaction of scopolamine in the best performing rats.
A H Herremans, and
T H Hijzen, and
B Olivier, and
J L Slangen
January 1992,
Psychopharmacology,
A H Herremans, and
T H Hijzen, and
B Olivier, and
J L Slangen
January 1989,
Psychopharmacology,
A H Herremans, and
T H Hijzen, and
B Olivier, and
J L Slangen
May 1991,
Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
A H Herremans, and
T H Hijzen, and
B Olivier, and
J L Slangen
August 2009,
Psicothema,
A H Herremans, and
T H Hijzen, and
B Olivier, and
J L Slangen
January 1996,
Psychopharmacology,
A H Herremans, and
T H Hijzen, and
B Olivier, and
J L Slangen
May 1979,
Physiology & behavior,
A H Herremans, and
T H Hijzen, and
B Olivier, and
J L Slangen
December 1994,
Pharmacology, biochemistry, and behavior,
A H Herremans, and
T H Hijzen, and
B Olivier, and
J L Slangen
August 2006,
Behavioural brain research,
A H Herremans, and
T H Hijzen, and
B Olivier, and
J L Slangen
April 2012,
Hippocampus,
A H Herremans, and
T H Hijzen, and
B Olivier, and
J L Slangen
January 1996,
Psychopharmacology,
